Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis

• Published in: Open medicine (Warsaw, Poland) Vol. 17; no. 1; pp. 863 - 870
• Main Authors: Su, Li, Huang, Yi, Zheng, Lei, Zhu, Zhifa, Wu, Yue, Li, Ping
• Format: Journal Article
• Language: English
• Published: Poland De Gruyter 06.05.2022; Walter de Gruyter GmbH
• Subjects: Cholangiocarcinoma; Dehydrogenases; Ferroptosis; IDH1; Mutation; mutation; ferroptosis; cholangiocarcinoma; IDH1
• ISSN: 2391-5463; 2391-5463
• DOI: 10.1515/med-2022-0477

The present study intends to clarify the hypothesis that isocitrate dehydrogenase 1 (IDH1) mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis through the and experiments. Cholangiocarcinoma RBE cell line was transfected with IDH1 R132C mutation plasmids and treated with erastin to induce ferroptosis, which were then microscopically photographed. Cell viability rate was calculated by trypan blue staining. The lipid ROS level was determined by using flow cytometer. The BALB/c nude mice were injected subcutaneously with IDH1 knockout (KO), WT, or R132C mutation cell line, followed by injecting erastin intraperitoneally. The tumor tissue was surgically separated for the measurement of tumor volume and weight. The results showed that IDH1 mutant RBE cell line are sensitive to erastin-induced ferroptosis, evidenced by the increased number of propidium iodide-positive cells, the decreased cell viability, and increased lipid ROS level. However, current targeted inhibitors of IDH1 mutation (AG120 and IDH305) reversed these effects caused by IDH1 mutation. The experiment showed that IDH1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to erastin-induced ferroptosis. This study indicated that IDH1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to erastin-induced ferroptosis.